Patrick McNutt to Antitoxins
This is a "connection" page, showing publications Patrick McNutt has written about Antitoxins.
Connection Strength
2.198
-
Machamer JB, Vazquez-Cintron EJ, O'Brien SW, Kelly KE, Altvater AC, Pagarigan KT, Dubee PB, Ondeck CA, McNutt PM. Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine. Mol Med. 2022 06 03; 28(1):61.
Score: 0.865
-
Vazquez-Cintron E, Machamer J, Ondeck C, Pagarigan K, Winner B, Bodner P, Kelly K, Pennington MR, McNutt P. Symptomatic treatment of botulism with a clinically approved small molecule. JCI Insight. 2020 01 30; 5(2).
Score: 0.736
-
Mukherjee J, Ondeck CA, Tremblay JM, Archer J, Debatis M, Foss A, Awata J, Erasmus JH, McNutt PM, Shoemaker CB. Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes. Sci Rep. 2022 Jul 08; 12(1):11664.
Score: 0.218
-
Winner BM, Bodt SML, McNutt PM. Special Delivery: Potential Mechanisms of Botulinum Neurotoxin Uptake and Trafficking within Motor Nerve Terminals. Int J Mol Sci. 2020 Nov 18; 21(22).
Score: 0.194
-
Lam KH, Tremblay JM, Vazquez-Cintron E, Perry K, Ondeck C, Webb RP, McNutt PM, Shoemaker CB, Jin R. Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins. Cell Rep. 2020 02 25; 30(8):2526-2539.e6.
Score: 0.185